ReviewMayo Clinic proceedings2009
Cardiac cell repair therapy: a clinical perspective.
Review in Mayo Clinic proceedings, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed.
- Review
- Delayed Intramyocardial Delivery of Stem Cells after Ischemia Reperfusion Injury in a Murine Model.Journal of visualized experiments : JoVE · 2020Article
- Selection of human induced pluripotent stem cells lines optimization of cardiomyocytes differentiation in an integrated suspension microcarrier bioreactor.Stem cell research & therapy · 2020Article
- Changing Metabolism in Differentiating Cardiac Progenitor Cells-Can Stem Cells Become Metabolically Flexible Cardiomyocytes?Frontiers in cardiovascular medicine · 2018Review
- Impaired redox environment modulates cardiogenic and ion-channel gene expression in cardiac-resident and non-resident mesenchymal stem cells.Experimental biology and medicine (Maywood, N.J.) · 2017Article
- Stem cell-based therapies to promote angiogenesis in ischemic cardiovascular disease.American journal of physiology. Heart and circulatory physiology · 2016Review
- Progenitor Hematopoietic Cells Implantation Improves Functional Capacity of End Stage Coronary Artery Disease Patients with Advanced Heart Failure.Cardiology research and practice · 2016Article
- Chronic High-Fat Feeding Affects the Mesenchymal Cell Population Expanded From Adipose Tissue but Not Cardiac Atria.Stem cells translational medicine · 2015Article
- Contemporary perspective on endogenous myocardial regeneration.World journal of stem cells · 2015Review
- Systems-based technologies in profiling the stem cell molecular framework for cardioregenerative medicine.Stem cell reviews and reports · 2015Review
- A novel cardiac muscle-derived biomaterial reduces dyskinesia and postinfarct left ventricular remodeling in a mouse model of myocardial infarction.Physiological reports · 2015Article
- Origin of cardiomyocytes in the adult heart.Circulation research · 2015Review
- Are Endothelial Progenitor Cells the Real Solution for Cardiovascular Diseases? Focus on Controversies and Perspectives.BioMed research international · 2015Review
- Regenerative medicine for the heart: perspectives on stem-cell therapy.Antioxidants & redox signaling · 2014Review
- Conjoint propagation and differentiation of human embryonic stem cells to cardiomyocytes in a defined microcarrier spinner culture.Stem cell research & therapy · 2014Article
- Renin inhibition improves the survival of mesenchymal stromal cells in a mouse model of myocardial infarction.Journal of cardiovascular translational research · 2014Article
- Article
- Noninvasive monitoring of oxidative stress in transplanted mesenchymal stromal cells.JACC. Cardiovascular imaging · 2013Article
- The pharmacology of regenerative medicine.Pharmacological reviews · 2013Review
- Natural ECM as biomaterial for scaffold based cardiac regeneration using adult bone marrow derived stem cells.Stem cell reviews and reports · 2013Review
Corrections and comments
- Commented on by
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
From bone marrow transplants 5 decades ago to the most recent stem cell-derived organ transplants, regenerative medicine is increasingly recognized as an emerging core component of modern practice. In cardiovascular medicine, innovation in stem cell biology has created curative solutions for the treatment of both ischemic and nonischemic cardiomyopathy. Multiple cell-based platforms have been developed, harnessing the regenerative potential of various natural and bioengineered sources. Clinical experience from the first 1000 patients (approximately) who have received stem cell therapy worldwide indicates a favorable safety profile with modest improvement in cardiac function and structural remodeling in the setting of acute myocardial infarction or chronic heart failure. Further investigation is required before early adoption and is ongoing. Broader application in practice will require continuous scientific advances to match each patient with the most effective reparative phenotype, while ensuring optimal cell delivery, dosing, and timing of intervention. An interdisciplinary effort across the scientific and clinical community within academia, biotechnology, and government will drive the successful realization of this next generation of therapeutic agents for the "broken" heart.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.